Literature DB >> 25118812

Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.

Minghao Zhong1, Wei Tian, Jian Zhuge, Xiaoyong Zheng, Tiangui Huang, Dongming Cai, David Zhang, Ximing J Yang, Pedram Argani, John T Fallon, Jonathan I Epstein.   

Abstract

Nested variant of urothelial carcinoma (NVUC) is an uncommon variant with minimally atypical cytology, which may overlap with benign urothelial lesions such as von Brunn nests, cystitis cystica, cystitis glandularis, and nephrogenic adenoma. Because of the tumor's deceptively bland appearance, these cancers can potentially be misdiagnosed as benign lesions, leading in some cases to a significant delay in correct diagnosis and appropriate treatment. Prior studies suggest that Ki67 and p53 are useful markers in distinguishing NVUC from benign lesions. However, the overlap in the rates of immunoreactivity has prevented pathologists from using these markers as reliable adjunct markers in differentiating NVUC from mimickers. In addition, large nested variant urothelial carcinoma (LNVUC), a relatively new entity, shares features of both the NVUC and papillary urothelial carcinomas with an inverted growth pattern. They also mimic benign lesions, such as proliferation of von Brunn nests and inverted urothelial papilloma. With the recent demonstration of a strong association of TERT promoter mutations and urothelial carcinoma, we hypothesized that TERT promoter mutations would be a useful marker to distinguish NVUC and LNVUC from other benign urothelial lesions. We have therefore sequenced the TERT promoter region of 20 cases of NVUC, 10 cases of LNVUC, 5 cases of von Brunn nests, 3 cases of cystitis cystica, 3 cases of cystitis glandularis, and 3 cases of nephrogenic adenoma. We found that 17 of 20 cases of NVUC and 8 of 10 cases of LNVUC had TERT promoter mutation: C228T; no mutation was found in any of the benign mimickers (0/14). This result strongly suggests that TERT promoter mutation is a useful adjunct biomarker to distinguish NVUC and LNVUC from benign mimickers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25118812     DOI: 10.1097/PAS.0000000000000305

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

1.  Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.

Authors:  Doreen N Palsgrove; Diana Taheri; Simeon U Springer; Morgan Cowan; Gunes Guner; Maria A Mendoza Rodriguez; Maria Del Carmen Rodriguez Pena; Yuxuan Wang; Isaac Kinde; Bernardo F P Ricardo; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth W Kinzler; Trinity J Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Hum Pathol       Date:  2018-11-14       Impact factor: 3.466

2.  Probe Sensitivity to Cortical versus Intracellular Cytoskeletal Network Stiffness.

Authors:  Amir Vahabikashi; Chan Young Park; Kristin Perkumas; Zhiguo Zhang; Emily K Deurloo; Huayin Wu; David A Weitz; W Daniel Stamer; Robert D Goldman; Jeffrey J Fredberg; Mark Johnson
Journal:  Biophys J       Date:  2019-01-07       Impact factor: 4.033

3.  Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.

Authors:  Morgan L Cowan; Simeon Springer; Doreen Nguyen; Diana Taheri; Gunes Guner; Maria Angelica Mendoza Rodriguez; Yuxuan Wang; Isaac Kinde; Maria Del Carmen Rodriguez Pena; Christopher J VandenBussche; Mathew T Olson; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth Kinzler; Trinity Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Hum Pathol       Date:  2016-03-10       Impact factor: 3.466

4.  [Specific types of bladder cancer].

Authors:  S Bertz; A Hartmann; R Knüchel-Clarke; N T Gaisa
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

5.  High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.

Authors:  Morgan Cowan; Simeon Springer; Doreen Nguyen; Diana Taheri; Gunes Guner; Maria Angelica Mendoza Rodriguez; Yuxuan Wang; Isaac Kinde; Christopher J VandenBussche; Matthew T Olson; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Trinity J Bivalacqua; Kenneth Kinzler; Bert Vogelstein; George J Netto; Nickolas Papadopoulos
Journal:  Mod Pathol       Date:  2016-03-11       Impact factor: 7.842

6.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.

Authors:  Somak Roy; Dinesh Pradhan; Wayne L Ernst; Stephanie Mercurio; Yana Najjar; Rahul Parikh; Anil V Parwani; Reetesh K Pai; Rajiv Dhir; Marina N Nikiforova
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

7.  High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.

Authors:  Doreen Nguyen; Diana Taheri; Simeon Springer; Morgan Cowan; Gunes Guner; Maria Angelica Mendoza Rodriguez; Yuxuan Wang; Isaac Kinde; Christopher J VandenBussche; Matthew T Olson; Bernardo F P Ricardo; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth W Kinzler; Trinity J Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Virchows Arch       Date:  2016-08-12       Impact factor: 4.064

Review 8.  [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].

Authors:  N Ortiz-Brüchle; M Muders; M Toma; I Esposito; A Hartmann; R Stöhr; H Reis; P Wild; J Köllermann; F Bremmer; J Leichsenring; A Stenzinger; S Merkelbach-Bruse; S Kirfel; S Perner; N Hartmann; W Roth; A Jung; T Kirchner; K Schwamborn; N Pfarr; E Dahl; R Knüchel; N T Gaisa
Journal:  Urologe A       Date:  2020-03       Impact factor: 0.639

Review 9.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

Review 10.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Authors:  Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt
Journal:  Nat Rev Urol       Date:  2020-03-31       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.